COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Dr Shazia Malik - a consultant obstetrician and gynaecologist for The Portland Hospital - discussed the pros and cons of ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

Serena Williams recently detailed her weight loss journey, sharing that she lost 31 pounds with the assistance of a GLP-1 ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...

In the past year or couple of years, you’ve likely heard a lot about Ozempic, most likely in the context of weight loss. Not ...

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...